JBIO vs NVAX

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

JBIO

32.9
AI Score
VS
NVAX Wins

NVAX

50.3
AI Score

Investment Advisor Scores

JBIO

33score
Recommendation
SELL

NVAX

50score
Recommendation
HOLD

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric JBIO NVAX Winner
Net Income -131.19M 440.30M NVAX
Operating Income -142.00M 452.80M NVAX
ROE -28.8% -344.7% JBIO
ROA -27.0% 37.4% NVAX
Total Assets 486.39M 1.18B NVAX
Cash 80.39M 240.63M NVAX
Current Ratio 16.03 2.13 JBIO

Relative Price Performance (Last 90 Days)

JBIO 1M: +17.3% · 3M: -31.2% NVAX 1M: -33.5% · 3M: +5.6%

Current Technical Phase

JBIO

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 58

RSI (14): 58.0 · Price: $16.14

NVAX

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 38

RSI (14): 37.7 · Price: $8.53

Fundamentals Snapshot

Metric JBIO NVAX
Market Cap — —
Forward P/E -6.1 -19.1
Trailing P/E — —
Revenue (TTM) — —
Revenue Growth 0.0% 0.0%
Gross Margin — 0.1%
Operating Margin 0.0% -0.2%
EPS -1.92 -0.52
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, NVAX is currently the stronger investment candidate, winning 5 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.